[Abstract] [Full Text PDF] (in Japanese / 1524KB) [Members Only And Two Factor Auth.]

J.Jpn. Surg. Soc.. 103(4): 359-363, 2002


Feature topic

CHEMOTHERAPY FOR THE PATIENTS WITH ESOPHAGEAL CANCER

Department of Surgery, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Japan

Nobutoshi Ando, Chih-Horng Shih

The combination of cisplatin and continuous-infusion 5-fluorouracil is the standard regimen for the treatment of both squamous cell carcinoma and adenocarcinoma. Paclitaxel has shown favorable results as a single agent or in combination with cisplatin. The efficacy of neoadjuvant chemotherapy in terms of survival benefit remains controversial despite large-scale, randomized, controlled trials comparing it with surgery alone. The disease-free survival benefit of postoperative adjuvant chemotherapy was recognized in a Japan Clinical Oncology Group randomized controlled trial in comparison with surgery alone.


<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.